Home - Chinese Journal of Cancer Research

2022 Impact Factor of CJCR: 5.1
Journal Citation Reports ™, Clarivate Analytics

National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

National Health Commission of the People’s Republic of China; Society of Oncology, Chinese Medical Association

CSCO guidelines for colorectal cancer version 2023: Updates and insights

Colorectal cancer (CRC) is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China. Since the first edition of the Chinese Society of Clinical Oncology (CSCO) guideline was published in 2017, the guideline has been updated annually according to the latest results of clinical research at home and abroad, the accessibility of drugs and the opinions of CSCO experts. Here, we present the main updates of the 2023 version compared to the 2022 version.

Stomach cancer burden in China: Epidemiology and prevention

In 2020, stomach cancer was the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related death worldwide. Due to the relatively huge population base and the poor survival rate, stomach cancer is still a threat in China, and accounts for nearly half of the cases worldwide. Fortunately, in China, the incidence and mortality rates of stomach cancer presented a declining trend owing to the change of individual life styles and the persistent efforts to prevent stomach cancer from the governments at all levels. Helicobacter pylori (H. pylori) infection, poor eating habits, smoking, history of gastrointestinal disorders, and family history of stomach cancer are the main risk factors for stomach cancer in China. As a result, by taking risk factors for stomach cancer into account, specific preventive measures, such as eradicating H. pylori and implementing stomach cancer screening projects, should be taken to better prevent and decrease the burden of stomach cancer.

Burden of liver cancer: From epidemiology to prevention

In this review, we offer a concise overview of liver cancer epidemiology in China and worldwide from the official databases of GLOBOCAN 2020 and the National Cancer Registry in China. We also summarized the evidence for the main risk factors associated with liver cancer risk and discuss strategies implemented in China to control the liver cancer burden. Overall, liver cancer was the sixth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide in 2020. Although China contributed to nearly half of cases across the world alone, the incidence and mortality rates of liver cancer presented a declining trend owing to the persistent efforts from the governments at all levels. The current liver cancer burden in China still faces an arduous challenge due to the relatively large population base as well as the substantially low survival rate (12.1%). To better control the liver cancer burden with the lowest cost, specific measures should be conducted by reducing exposure to established risk factors such as hepatitis B infection and aflatoxin.

‹ ›

Vol 35, No 5 (Oct 2023)

Editorial

Comments on National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

Yong Yang, Zhaoya Gao, Jin Gu

Pages: 431-432 HTML

Perspective

Advances, breakthroughs, and challenges in gastric cancer surgery

Hayun Kim, Sungsoo Park

Pages: 433-437 HTML

Review Article

Epidemiology of pancreatic cancer: New version, new vision

Wenhao Luo, Jun Wang, Hao Chen, Liyuan Ye, Jiangdong Qiu, Yueze Liu, Ruobing Wang, Guihu Weng, Tao Liu, Dan Su, Jinxin Tao, Chen Ding, Lei You, Taiping Zhang

Pages: 438-450 HTML

MRD-directed and risk-adapted individualized stratified treatment of AML

Yijing Zhao, Hanfei Guo, Yingjun Chang

Pages: 451-469 HTML

Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine

Yang Liu, Ya-nan Ren, Yan Cui, Song Liu, Zhi Yang, Hua Zhu, Nan Li

Pages: 470-482 HTML

Update of latest data for combined therapy for esophageal cancer using radiotherapy and immunotherapy: A focus on efficacy, safety, and biomarkers

Shuping Cheng, Butuo Li, Jinming Yu, Linlin Wang

Pages: 483-500 HTML

Original Article

Genetic susceptibility loci of lung cancer are associated with malignant risk of pulmonary nodules and improve malignancy diagnosis based on CEA levels

Zhi Li, Liming Lu, Yibin Deng, Amei Zhuo, Fengling Hu, Wanwen Sun, Guitian Huang, Linyuan Liu, Boqi Rao, Jiachun Lu, Lei Yang

Pages: 501-510 HTML

A novel multimodal prediction model based on DNA methylation biomarkers and low-dose computed tomography images for identifying early-stage lung cancer

Jing Zhang, Haohua Yao, Chunliu Lai, Xue Sun, Xiujuan Yang, Shurong Li, Yubiao Guo, Junhang Luo, Zhihua Wen, Kejing Tang

Pages: 511-525 HTML

Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib

Jianwei Zhang, Haibin Zhu, Lin Shen, Jie Li, Xiaoyan Zhang, Chunmei Bai, Zhiwei Zhou, Xianrui Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Wenhui Lou, Yihebali Chi, Nong Xu, Yongmei Yin, Yuxian Bai, Tao Zhang, Dianrong Xiu, Jia Chen, Shukui Qin, Xiuwen Wang, Yujie Yang, Haoyun Shi, Xian Luo, Songhua Fan, Weiguo Su, Ming Lu, Jianming Xu

Pages: 526-535 HTML

Genetic abnormalities assist in pathological diagnosis and EBV-positive cell density impact survival in Chinese angioimmunoblastic T-cell lymphoma patients

Yunfei Shi, Haojie Wang, Yanfei Liu, Mengping Long, Ning Ding, Lan Mi, Yumei Lai, Lixin Zhou, Xinting Diao, Xianghong Li, Weiping Liu, Jun Zhu

Pages: 536-549 HTML

OpenNAU: An open-source platform for normalizing, analyzing, and visualizing cancer untargeted metabolomics data

Qingrong Sun, Qingqing Xu, Majie Wang, Yongcheng Wang, Dandan Zhang, Maode Lai

Pages: 550-562 HTML

NHCPRC Guidelines

National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

National Health Commission of the People’s Republic of China; Society of Oncology, Chinese Medical Association

Pages: 197-232 HTML